Loading...

IONS IONIS PHARMACEUTICALS INC Company Mergers 8-K Filing

NS P

NS

IONIS PHARMACEUTICALS INC

(IONS)

2025 8-K

Convertible Notes Offering

Positive Drug Results

Advisory Agreement

Financial Results

Positive Study Results

Positive Study Results

FDA Approval Announcement

Financial Statements

New Product Launches

Financial Statements

License Agreement

Financial Results

Financial Results

Earnings Reports

License Agreement with Otsu...

Annual Meeting of Stockholders

Positive Results Announcement

Financial Results Announcement

Positive Results from Phase...

Management Changes

Financial Results Announcement

License Agreement with Otsu...

Appointment of Michael Yang...

Financial Results Announcement

Agreement with Roche for RN...

Agreements for Note Repurchase

Property Sale and Lease Agr...

Financial Results Announcement

Termination of Lease Agreement

Collaboration Agreement wit...

Private Offering of Convert...

Annual Meeting of Stockholders

Financial Results Announcement

Positive Study Results for ...

External Links:

On March 11, 2025, Ionis Pharmaceuticals announced a license agreement with Ono Pharmaceutical for exclusive global rights to develop and commercialize sapablursen, a treatment for polycythemia vera.

AI Assistant

IONIS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.